Off-label use of bone morphogenetic proteins in the United States using administrative data

Spine

Volumn 35, Issue 19, 2010, Pages 1794-1800

  Ong, Kevin L ^a   Villarraga, Marta L ^a   Lau, Edmund ^a   Carreon, Leah Y ^b   Kurtz, Steven M ^a   Glassman, Steven D ^b  

^a EXPONENT INC   (United States)

^b NORTON LEATHERMAN SPINE CENTER   (United States)

Author keywords

bone morphogenetic protein; epidemiology; FDA; fusion; Nationwide Inpatient Sample; offlabel

Indexed keywords

BONE MORPHOGENETIC PROTEIN;

ANTERIOR LUMBAR INTERBODY FUSION; ARTICLE; CERVICAL SPINE FUSION; DRUG LABELING; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; POSTERIOR LUMBAR INTERBODY FUSION; PRIORITY JOURNAL; SPINE FUSION; SURGICAL APPROACH; TRANSFORAMINAL LUMBAR INTERBODY FUSION; UNITED STATES;

ADULT; AGED; BONE MORPHOGENETIC PROTEINS; DATABASES AS TOPIC; DRUG LABELING; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HEALTH CARE SURVEYS; HEALTHCARE DISPARITIES; HUMANS; INPATIENTS; MALE; MIDDLE AGED; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; REOPERATION; RISK ASSESSMENT; SPINAL FUSION; TIME FACTORS; UNITED STATES;

EID: 77956419392     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181ecf6e4     Document Type: Article

References (43)

1. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-899
2. Goulet JA, Senunas LE, DeSilva GL, et al. Autogenous iliac crest bone graft: complications and functional assessment. Clin Orthop Relat Res 1997:76-81.
3. Pollock R, Alcelik I, Bhatia C, et al. Donor site morbidity following iliac crest bone harvesting for cervical fusion: a comparison between minimally invasive and open techniques. Eur Spine J 2008;17:845-852
4. Boakye M, Mummaneni PV, Garrett M, et al. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine 2005;2:521-525
5. Dimar JR II, Glassman SD, Burkus JK, et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J Bone Joint Surg Am 2009;91: 1377-1386
6. Glassman SD, Carreon LY, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine 2008;33:2843-2849
7. Haid RW Jr, Branch CL Jr, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004;4:527-38; discussion 38-39
8. Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone mor-phogenetic protein-2. J Neurosurg Spine 2005;3:436-443
9. US Food and Drug Administration. 0P-1-H010002, 2001. Available at: ApprovalsandClearances/Recently-ApprovedDevices/ucm085026.htm. Accessed June 18,2009.
10. US Food and Drug Administration. InFUSE Bone graft/LT-CAGE lumbar tapered fusion device-P000058,2002. Available at: MedicalDevices/ ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently- ApprovedDevices/ucm083423.htm. Accessed June 18, 2009.
11. US Food and Drug Administration. OP-1 Putty -H020008, 2004. Available at: DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm081181. htm. Accessed June 18, 2009.
12. US Food and Drug Administration. INFUSE/MASTERGRAFT posterolat-eral revision device-H040004, 2008. Available at: . fda.gov/scripts/cdrh/cfdocs/ cftopic/pma/pma.cfm?num = H040004. Accessed June 18,2009.
13. US Food and Drug Administration. INFUSE Bone graft-P000054, 2004. Available at: Procedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ ucm081154.htm. Accessed June 18, 2009.
14. US Food and Drug Administration. INFUSE Bone Graft-P050053, 2007. Available at: Procedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ ucm077024.htm. Accessed June 18, 2009.
15. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008;8:1011-1018
16. Lewandrowski KU, Nanson C, Calderon R. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphoge-netic protein 2: a report of five cases. Spine J 2007;7:609-614
17. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006;19:483-486
18. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006;31:542-547
19. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 2006;31:2813-2819
20. Crawford CH III, Carreon LY, McGinnis MD, et al. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorb-able collagen sponge versus iliac crest bone graft for posterior cervical arth-rodesis. Spine 2009;34:1390-1394
21. Hiremath GK, Steinmetz MP, Krishnaney AA. Is it safe to use recombinant human bone morphogenetic protein in posterior cervical fusion? Spine 2009; 34:885-889
22. US Food and Drug Administration. Life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion, 2007. Available at: AlertsandNotices/PublicHealthNotifications/ ucm062000.htm. Accessed June 18, 2009.
23. Agency for Healthcare Research and Quality. HCUP databases. Healthcare Cost and Utilization Project (HCUP). 2008. Available at: http://www.hcup-us. ahrq.gov/nisoverview.jsp. Accessed January 9, 2009.
24. Jain NB, Guller U, Pietrobon R, et al. Comorbidities increase complication rates in patients having arthroplasty. Clin Orthop Relat Res 2005:232-238
25. Deyo RA, Gray DT, Kreuter W, et al. United States trends in lumbar fusion surgery for degenerative conditions. Spine 2005;30:1441-5; discussion 6-7.
26. US Food and Drug Administration. Guidance for industry-good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices, 2009. Available at: . gov/oc/op/ goodreprint.html. Accessed August 14, 2009.
27. American Academy of Orthopaedic Surgeons. Position statement: off-label use of medical products, 2009. Available at: http://www.aaos.org/about/ >papers/position/1177.asp. Accessed August 13, 2009.
28. Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone mor-phogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002;27:2662-2673
29. Burkus JK, Heim SE, Gornet MF, et al. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech 2003;16:113-122
30. Schrader K, Altmire J, Bean M, et al. H.R. 2502-Comparative Effectiveness Research Act of2009, 2009. Available at: 111-h2502/show. Accessed August 26, 2009.
31. Faciszweski T, Bean JR, Asher AL, et al. Comment on potential National Coverage Determination (NCD), 2008. Available at: Documentsfinal-NCD-response- 092808.pdf. Accessed August 18, 2009.
32. Mindea SA, Shih P, Song JK. Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine 2009;34:1480 -4; discussion 5.
33. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J 2009;9:623-629
34. Sekiya I, Tang T, Hayashi M, et al. Periodic knee injections of BMP-7 delay cartilage degeneration induced by excessive running in rats. J Orthop Res 2009;27:1088-1092
35. Masuda K, Imai Y, Okuma M, et al. Osteogenic protein-1 injection into a degenerated disc induces the restoration of disc height and structural changes in the rabbit anular puncture model. Spine 2006;31:742-754
36. Cook SD, Salkeld SL, Patron LP. Bone defect healing with an osteogenic protein-1 device combined with carboxymethylcellulose. J Biomed Mater Res B Appl Biomater 2005;75:137-145
37. Lieberman JR, Conduah A, Urist MR. Treatment of osteonecrosis of the femoral head with core decompression and human bone morphogenetic protein. Clin Orthop Relat Res 2004:139-145
38. Cook SD, Barrack RL, Patron LP, et al. Osteogenic protein-1 in knee arthritis and arthroplasty. Clin Orthop Relat Res 2004:140-145
39. Shih C, Berliner E. Diffusion of new technology and payment policies: coronary stents. Health Aff (Millwood) 2008;27:1566-1576
40. Hashimoto H, Noguchi H, Heidenreich P, et al. The diffusion of medical technology, local conditions, and technology re-invention: a comparative case study on coronary stenting. Health Policy 2006;79:221-230
41. Carreon LY, Glassman SD, Djurasovic M, et al. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion in patients over 60 years of age: a cost-utility study. Spine 2009;34:238-243
42. Polly DW Jr, Ackerman SJ, Shaffrey CI, et al. A cost analysis of bone mor-phogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion. Orthopedics 2003;26:1027-1037
43. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009;302:58-66.